The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
SOCCAR: Sequential or concurrent chemotherapy and hypofractionated accelerated radiotherapy in inoperable stage III NSCLC.
J. Maguire
Consultant or Advisory Role - Pierre Fabre Medicament
Honoraria - Pierre Fabre Medicament
R. McMenemin
No relevant relationships to disclose
N. O'Rourke
No relevant relationships to disclose
C. Peedell
No relevant relationships to disclose
M. Snee
No relevant relationships to disclose
S. McNee
No relevant relationships to disclose
V. Kelly
No relevant relationships to disclose